港股创新药概念股早盘走低，科伦博泰生物-B跌超7%，百济神州、三生制药跌超5%，康方生物、翰森 制药跌超4%。 受盘面影响，港股创新药相关ETF跌约2%。 | 代码 | 名称 | 现价 | | 涨跌 涨跌幅 ▲ | | --- | --- | --- | --- | --- | | 159297 | 港股通创新药ETF南方 | 0.837 | -0.019 | -2.22% | | 159570 | 港股通创新药ETF | 1.651 | -0.037 | -2.19% | | 159217 | 港股通创新药ETF工银 | 1.340 | -0.029 | -2.12% | | 159567 | 港股创新药ETF | 0.799 | -0.017 | -2.08% | | 159286 | 港股创新药ETF鹏华 | 0.855 | -0.016 | -1.84% | 有券商表示，从企业层面看，越来越多创新药企业从"研发投入期"进入"商业化兑现期"，核心产品销售 收入稳步增长，部分企业实现从减亏到盈利的跨越，为股价提供坚实支撑。同时，公募基金等机构对优 质标的配置比例提升，市场认可度持续提高。创新药行情的核心也 ...

港股创新药ETF鹏华（159286）业绩比较基准为国证港股通创新药指数收益率(经汇率调整后)，管理人 为鹏华基金管理有限公司，基金经理为林嵩、张羽翔，成立（2025-08-20）以来回报为-13.25%，近一 个月回报为-2.02%。 来源：新浪基金∞工作室 12月10日，港股创新药ETF鹏华（159286）跌0.12%，成交额2763.45万元。当日份额增加100.00万份， 最新份额为6.78亿份，近20个交易日份额减少2500.00万份。最新资产净值计算值为5.88亿元。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 ...

Group 1 - The Hong Kong Innovative Drug ETF Penghua (159286) experienced a decline of 1.72% on November 18, with a trading volume of 83.8677 million yuan [1] - The fund's shares increased by 3 million, bringing the total shares to 673 million, with a total increase of 63 million shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated to be 613 million yuan [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug ETF Penghua is the National Index of Hong Kong Innovative Drugs, adjusted for exchange rates [1] - The fund is managed by Penghua Fund Management Co., Ltd., with fund managers Lin Song and Zhang Yuxiang [1] - Since its establishment on August 20, 2025, the fund has returned -8.91%, with a return of -0.55% over the past month [1]

港股创新药ETF鹏华（159286）业绩比较基准为国证港股通创新药指数收益率(经汇率调整后)，管理人 为鹏华基金管理有限公司，基金经理为林嵩、张羽翔，成立（2025-08-20）以来回报为-5.05%，近一个 月回报为-0.05%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 来源：新浪基金∞工作室 11月13日，港股创新药ETF鹏华（159286）涨4.40%，成交额1.77亿元。当日份额减少2500.00万份，最 新份额为6.78亿份，近20个交易日份额增加8400.00万份。最新资产净值计算值为6.44亿元。 ...

Group 1 - The core viewpoint indicates that the innovative drug sector in Hong Kong is showing clear signs of bottoming out, supported by several factors [1] - BD (Business Development) transactions have started to recover since October, with historical data showing that transactions from October to January account for over 50% of the annual total, and transaction amounts can reach 60% to 70% of the yearly total [1] - Positive data from ESMO (European Society for Medical Oncology) has emerged, with several important clinical studies, such as AK112 and 3SB707, showing promising results, which is expected to catalyze further trading and stock price increases [1] - The valuation of innovative drugs has reached an absolute bottom, with some companies having little room for further decline [1] Group 2 - As of October 21, 2025, the National Securities Hong Kong Stock Connect Innovative Drug Index (987018) shows mixed performance among its constituent stocks, with notable gainers including CloudTop New Drug (01952) up 5.29% and Zai Lab (09688) up 1.80%, while major decliners include Juno Therapeutics-B (02617) down 6.82% [2] - The Hong Kong Innovative Drug ETF (159286) closely tracks the National Securities Hong Kong Stock Connect Innovative Drug Index and has seen a slight increase of 0.22%, with the latest price at 0.93 yuan [2] - As of September 30, 2025, the top ten weighted stocks in the National Securities Hong Kong Stock Connect Innovative Drug Index account for 71.83% of the index, including companies like BeiGene (06160) and Innovent Biologics (09926) [2]

Core Viewpoint - The Hong Kong Innovative Drug ETF Penghua (159286) experienced a 2.37% increase in value on October 16, with a trading volume of 217 million yuan, indicating positive market sentiment towards innovative drug investments [1] Group 1: Fund Performance - The fund's latest net asset value is calculated at 562 million yuan [1] - The fund's shares increased by 7 million to a total of 594 million shares, with a notable increase of 98 million shares over the past 20 trading days [1] - Since its inception on August 20, 2025, the fund has reported a return of -5.38%, while the return over the past month is -7.86% [1] Group 2: Management and Benchmark - The fund is managed by Penghua Fund Management Co., Ltd., with fund managers Lin Song and Zhang Yuxiang overseeing its operations [1] - The performance benchmark for the fund is the Guozhen Hong Kong Stock Connect Innovative Drug Index return (adjusted for exchange rates) [1]

Core Viewpoint - The Hong Kong Innovative Drug ETF managed by Penghua experienced a decline of 2.30% on October 10, with a trading volume of 121 million yuan, indicating a challenging market environment for innovative drug investments [1] Fund Performance - The fund's latest net asset value is calculated at 538 million yuan, with a total share increase of 10 million shares on the same day, bringing the total shares to 559 million [1] - Over the past 20 trading days, the fund's shares have decreased by 41 million [1] - Since its inception on August 20, 2025, the fund has returned -3.67%, while the return over the past month is -5.25% [1] Management Information - The fund is managed by Penghua Fund Management Co., Ltd., with fund managers Lin Song and Zhang Yuxiang overseeing its operations [1]

Core Viewpoint - The Hong Kong Innovative Drug ETF managed by Penghua experienced a slight decline of 0.30% on September 17, with a trading volume of 98.91 million yuan and a reduction of 10 million shares, bringing the total shares to 534 million [1] Group 1: Fund Performance - The latest net asset value of the Hong Kong Innovative Drug ETF is 543 million yuan [1] - Since its establishment on August 20, 2025, the fund has achieved a return of 1.77% [1] Group 2: Management Information - The fund is managed by Penghua Fund Management Co., Ltd., with fund managers Lin Song and Zhang Yuxiang [1] - The performance benchmark for the fund is the National Index of Hong Kong Stock Connect Innovative Drug Index, adjusted for exchange rates [1]